Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Pia Sormani

Showing results (21-30 of 390) with videos related to

Pageof 39
Sort By:
European Journal of Clinical Pharmacology|March 1, 2012
Indirect comparisons of treatment effects in multiple sclerosisMaria Pia Sormani, Alessio Signori
Nature Reviews. Neurology|December 24, 2014
Can we measure long-term treatment effects in multiple sclerosis?Maria Pia Sormani, Paolo Bruzzi
Nature Reviews. Neurology|September 15, 2020
Comparative effectiveness of rituximab in multiple sclerosisTomas Kalincik, Maria Pia Sormani
Neurology|March 24, 2022
Accelerating Clinical Trials of New Therapies for Progressive Multiple Sclerosis: Thinking AnewDennis Bourdette, Maria Pia Sormani
Nature Reviews. Neurology|June 20, 2020
Combining biomarkers to profile multiple sclerosis patientsNicola De Stefano, Maria Pia Sormani
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 5, 2014
MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: yesMaria Pia Sormani, Nicola De Stefano
Neurology|October 24, 2019
Measuring disability in multiple sclerosis: Walking plus much moreMaria Pia Sormani, R T Naismith
Nature Reviews. Neurology|July 31, 2013
Defining and scoring response to IFN-β in multiple sclerosisMaria Pia Sormani, Nicola De Stefano
Neurology|April 1, 2014
Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapyMaria Pia Sormani, Nicola De Stefano
Neurology|February 13, 2020
Tracking therapies in MS: More evidence in favor of neurofilamentE Ann Yeh, Maria Pia Sormani
Pageof 39

Showing results (21-30 of 390) with videos related to

Sort By:
Pageof 39
European Journal of Clinical Pharmacology|March 1, 2012
Indirect comparisons of treatment effects in multiple sclerosisMaria Pia Sormani, Alessio Signori
Nature Reviews. Neurology|December 24, 2014
Can we measure long-term treatment effects in multiple sclerosis?Maria Pia Sormani, Paolo Bruzzi
Nature Reviews. Neurology|September 15, 2020
Comparative effectiveness of rituximab in multiple sclerosisTomas Kalincik, Maria Pia Sormani
Neurology|March 24, 2022
Accelerating Clinical Trials of New Therapies for Progressive Multiple Sclerosis: Thinking AnewDennis Bourdette, Maria Pia Sormani
Nature Reviews. Neurology|June 20, 2020
Combining biomarkers to profile multiple sclerosis patientsNicola De Stefano, Maria Pia Sormani
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 5, 2014
MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: yesMaria Pia Sormani, Nicola De Stefano
Neurology|October 24, 2019
Measuring disability in multiple sclerosis: Walking plus much moreMaria Pia Sormani, R T Naismith
Nature Reviews. Neurology|July 31, 2013
Defining and scoring response to IFN-β in multiple sclerosisMaria Pia Sormani, Nicola De Stefano
Neurology|April 1, 2014
Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapyMaria Pia Sormani, Nicola De Stefano
Neurology|February 13, 2020
Tracking therapies in MS: More evidence in favor of neurofilamentE Ann Yeh, Maria Pia Sormani
Pageof 39